PANCRAZZI, ALESSANDRO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 4.535
EU - Europa 3.512
AS - Asia 1.407
SA - Sud America 170
AF - Africa 38
OC - Oceania 25
Continente sconosciuto - Info sul continente non disponibili 1
Totale 9.688
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.510
PL - Polonia 1.370
RU - Federazione Russa 941
SG - Singapore 377
HK - Hong Kong 366
CN - Cina 319
IT - Italia 260
IE - Irlanda 233
SE - Svezia 225
BR - Brasile 137
DE - Germania 130
KR - Corea 120
FI - Finlandia 77
VN - Vietnam 70
UA - Ucraina 68
FR - Francia 61
GB - Regno Unito 57
IN - India 55
CH - Svizzera 45
JO - Giordania 28
AU - Australia 24
CA - Canada 15
ID - Indonesia 15
AR - Argentina 14
TR - Turchia 13
NL - Olanda 11
CI - Costa d'Avorio 10
ES - Italia 9
BD - Bangladesh 8
MX - Messico 8
BG - Bulgaria 7
EC - Ecuador 6
JP - Giappone 6
MA - Marocco 6
ZA - Sudafrica 6
BE - Belgio 5
DZ - Algeria 5
AE - Emirati Arabi Uniti 4
BO - Bolivia 4
IQ - Iraq 4
AT - Austria 3
EG - Egitto 3
KE - Kenya 3
LT - Lituania 3
PH - Filippine 3
TW - Taiwan 3
UZ - Uzbekistan 3
VE - Venezuela 3
KG - Kirghizistan 2
PY - Paraguay 2
SC - Seychelles 2
SK - Slovacchia (Repubblica Slovacca) 2
BH - Bahrain 1
BJ - Benin 1
CD - Congo 1
CL - Cile 1
CZ - Repubblica Ceca 1
EU - Europa 1
GE - Georgia 1
GY - Guiana 1
HN - Honduras 1
IL - Israele 1
IM - Isola di Man 1
KZ - Kazakistan 1
LB - Libano 1
LK - Sri Lanka 1
MK - Macedonia 1
MY - Malesia 1
NO - Norvegia 1
NZ - Nuova Zelanda 1
PA - Panama 1
PK - Pakistan 1
PS - Palestinian Territory 1
RO - Romania 1
SA - Arabia Saudita 1
SR - Suriname 1
TH - Thailandia 1
TN - Tunisia 1
UY - Uruguay 1
Totale 9.688
Salva come PNG Salva come JPEG
Città #
Warsaw 1.369
Santa Clara 971
Fairfield 534
Ashburn 426
Hong Kong 322
Chandler 279
Woodbridge 232
Dublin 231
Singapore 227
Seattle 218
Cambridge 193
Houston 190
Wilmington 165
Seoul 120
Beijing 119
Jacksonville 111
Ann Arbor 86
Altamura 73
Lawrence 67
Buffalo 66
Princeton 63
Los Angeles 55
Dallas 45
Bern 44
Boston 44
Mumbai 38
Bremen 35
Hefei 34
Boardman 33
Shanghai 31
New York 30
Florence 25
Medford 25
Moscow 25
Munich 24
San Diego 24
Melbourne 23
São Paulo 18
Dearborn 16
Dong Ket 16
The Dalles 16
Helsinki 15
Ho Chi Minh City 14
London 14
Paris 14
Phoenix 14
Redondo Beach 14
Clifton 13
Kent 13
Hanoi 12
Jakarta 12
Montepulciano 12
Norwalk 11
Turku 11
Abidjan 10
Falls Church 8
Pune 8
Redwood City 8
Salerno 8
Barcelona 7
Brooklyn 7
Fuzhou 7
Izmir 7
Milan 7
Montreal 7
Andover 6
Auburn Hills 6
Frankfurt am Main 6
Hillsboro 6
Pian di Scò 6
Sofia 6
West Jordan 6
Cantagallo 5
Guayaquil 5
Newham 5
San Francisco 5
Yubileyny 5
Abu Dhabi 4
Belo Horizonte 4
Brasília 4
Brussels 4
Council Bluffs 4
Frankfurt Am Main 4
Mexico City 4
Nanjing 4
Newark 4
Old Bridge 4
Orem 4
Romainville 4
Rome 4
Sétif 4
Tokyo 4
Turin 4
Amman 3
Casablanca 3
Changsha 3
Chennai 3
Chicago 3
Guangzhou 3
Hangzhou 3
Totale 7.068
Salva come PNG Salva come JPEG
Nome #
Abnormalities of GATA-1 in megakaryocytes from patients with idiopathic myelofibrosis. 353
Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele. 326
Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia. 319
GROWTH INHIBITION AND DIFFERENTIATION OF HUMAN BREAST CANCER CELLS BY THE PAFR ANTAGONIST WEB-2086 318
Frequency and clinical correlates of JAK2 46/1 (GGCC) haplotype in primary myelofibrosis. 316
A sensitive detection method for MPLW515L or MPLW515K mutation in chronic myeloproliferative disorders with locked nucleic acid-modified probes and real-time polymerase chain reaction. 315
Increased risk of lymphoid neoplasms in patients with Philadelphia chromosome-negative myeloproliferative neoplasms. 315
Validation of the differential prognostic impact of type 1/type 1-like versus type 2/type 2-like CALR mutations in myelofibrosis 310
B-, T-, and NK-cell lineage involvement in JAK2V617F-positive patients with idiopathic myelofibrosis. 287
Spleen endothelial cells from patients with myelofibrosis harbor the JAK2V617F mutation 281
Impact of JAK2(V617F) mutation status on treatment response to anagrelide in essential thrombocythemia: An observational, hypothesis-generating study 277
Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombocythemia. 237
Epidemiology and clinical relevance of mutations in post-polycythemia vera and post-essential thrombocythemia myelofibrosis. A study on 359 patients of the AGIMM group 219
Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients 206
Molecular profiling of CD34+ cells in idiopathic myelofibrosis identifies a set of disease-associated genes and reveals the clinical significance of Wilms' tumor gene 1 (WT1). 201
Targeted deep sequencing in polycythemia vera and essential thrombocythemia 195
MicroRNA expression profile in granulocytes from primary myelofibrosis patients. 189
Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis 186
Involvement of RUNX1 Pathway Is a Common Event in the Leukemic Transformation of Chronic Myeloproliferative Neoplasms (MPNs) 184
Clonal architecture of JAK2V617F mutated cells during treatment with ruxolitinib 183
Mutations and prognosis in primary myelofibrosis. 177
JAK2V617F complete molecular remission in polycythemia vera/essential thrombocythemia patients treated with ruxolitinib 177
Inconsistencies in the association between the JAL2V617F mutation and PRV-1 over-expression among the chronic myeloproliferative diseases 175
Mutation landscape in patients with myelofibrosis receiving ruxolitinib or hydroxyurea 171
A QUANTITATIVE ASSAY FOR JAK2V617F MUTATION IN MYELOPROLIFERATIVE DISORDERS BY ARMS-PCR AND CAPILLARY ELECTROPHORESIS 168
Clinical implications of the JAK2 V617F mutation in essential thrombocythemia. 167
Targeted cancer exome sequencing reveals recurrent mutations in myeloproliferative neoplasms. 163
Infrequent occurrence of mutations in the PH domain of LNK in patients with JAK2 mutation-negative 'idiopathic' erythrocytosis. 159
Acquired copy-neutral loss of heterozygosity of chromosome 1p as a molecular event associated with marrow fibrosis in MPL-mutated myeloproliferative neoplasms. 157
Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis 151
Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia. 147
The number of prognostically detrimental mutations and prognosis in primary myelofibrosis: an international study of 797 patients. 145
Neutrophilic progression in a case of polycytemia vera mimicking chronic neutrophilic leukemia: Clinical and molecular characterization. 143
A pathobiological pathway linking thrombopoietin, GATA1 and TGFbeta1 in the development of myelofibrosis 140
CALR and ASXL1 mutations-based molecular prognostication in primary myelofibrosis: an international study of 570 patients. 140
WEB-2086 and WEB-2170 trigger apoptosis in both ATRA-sensitive and -resistant promyelocytic leukemia cells and greatly enhance ATRA differentiation potential 138
Recommendations for molecular testing in classical Ph1-neg myeloproliferative disorders–A consensus project of the Italian Society of Hematology 138
Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden. 137
Anaemia characterises patients with myelofibrosis harbouring Mpl mutation. 136
PRV-1, erythroid colonies and platelet Mpl are unrelated to thrombosis in essential thrombocythaemia. 136
Calreticulin Mutation Is Associated with Milder Disease in Patients with Post Essential Thrombocythemia Myelofibrosis (PET-MF) Compared with JAK2V617F Mutation: A Study from the AGIMM Group 135
Establishing optimal quantitative-polymerase chain reaction assays for routine diagnosis and tracking of minimal residual disease in JAK2-V617F-associated myeloproliferative neoplasms: a joint European LeukemiaNet/MPN&MPNr-EuroNet (COST action BM0902) study. 135
CXCR4-independent rescue of the myeloproliferative defect of the Gata1low myelofibrosis mouse model by Aplidin. 130
Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. 123
ANALISI MUTAZIONALI DELLE MALATTIE MIELOPROLIFERTAIVE CRONICHE 119
MPL mutational analysis in chronic myeloproliferative disorders 117
Variegation of the phenotype induced by the GATA-1low mutation in mice of different genetic backgrounds. 117
A genome-wide association study for survival from a multi-centre European study identified variants associated with COVID-19 risk of death 112
Analisi mutazionale delle malattie mieloproliferative croniche 104
Internal tandem duplication of FLT3 gene (FLT3/TID) predicts a poor post-remission outcome in adult patients witha cute non-promyelocytic leukemia 89
Primary myelofibrosis with or without mutant MPL: comparison ofsurvival and clinical features involving 603 patients. 86
Percorsi diagnostici-terapeutici per le neoplasie mieloproliferative nella AOU Careggi 86
ANALYSIS OF ASXL1 MUTATIONS IN 215 PATIENTS WITH MYELOFIBROSIS : IMPACT ON DISEASE PHENOTYPE AND PROGNOSIS 81
LNK MUTATIONS IN JAK2 NEGATIVE ERYTHROCYTOSIS 57
Totale 9.773
Salva come PNG Salva come JPEG
Categoria #
all - tutte 25.137
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 25.137
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021467 0 0 0 0 0 70 42 75 64 113 48 55
2021/2022415 22 43 34 16 15 12 17 35 14 9 88 110
2022/20231.170 98 218 67 115 87 193 136 69 105 3 31 48
2023/2024369 13 45 56 17 39 74 11 59 3 14 25 13
2024/20252.748 76 271 196 383 775 432 18 227 139 67 86 78
2025/20261.302 332 307 183 184 287 9 0 0 0 0 0 0
Totale 9.773